Frontlight ResearchEarly access
Liver and biliary tract cancer trials in China
621 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- No phaseNot yet taking people in ChinaThe Application Value of Spectral CT in the Accurate Staging of Liver Cancer
- Where
- Kunming
- Age
- 18 years to 80 years
- People
- 150
- Run by
- Yunnan Cancer Hospital
See details and how to joinNCT06977399 - Phase 2Taking peopleFGF19 Overexpression Combination Unified Study in HCC-19
- Where
- Shanghai
- Age
- 18 years and over
- People
- 42
- Run by
- RenJi Hospital
See details and how to joinNCT06978933 - No phaseTaking peopleClinical Study on the Safety and Efficacy of QY-1-T in the Treatment of HBV-associated Advanced HCC
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 9
- Run by
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT06251115 - Phase 2Taking peopleA Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib
- Where
- Fuzhou
- Age
- 18 years to 75 years
- People
- 40
- Run by
- Meng Chao Hepatobiliary Hospital of Fujian Medical University
See details and how to joinNCT06280105 - Early phase 1Taking peopleNeoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Resection
- Where
- Fuzhou
- Age
- 18 years to 75 years
- People
- 10
- Run by
- Yongyi Zeng
See details and how to joinNCT06406816 - Early phase 1Taking peopleStudy on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma
- Where
- Wuhan
- Age
- 18 years to 65 years
- People
- 100
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT06383520 - No phaseTaking peopleA Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma
- Where
- Fuzhou
- Age
- 18 years to 75 years
- People
- 300
- Run by
- Meng Chao Hepatobiliary Hospital of Fujian Medical University
See details and how to joinNCT05409482 - Phase 1Taking peopleA Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 122
- Run by
- HC Biopharma Inc.
See details and how to joinNCT06307925 - Phase 1Taking peopleAutologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma
- Where
- Beijing
- Age
- 18 years to 70 years
- People
- 10
- Run by
- Lion TCR Pte. Ltd.
See details and how to joinNCT06961617 - Phase 2Enrolling by invitationGem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 44
- Run by
- Wei Gong
See details and how to joinNCT06963060 - Phase 2Taking peopleCadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma
- Where
- Chengdu
- Age
- 18 years to 75 years
- People
- 51
- Run by
- West China Hospital
See details and how to joinNCT06438822 - Phase 1/2Taking peoplePersonalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma
- Where
- Hangzhou
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Zhejiang University
See details and how to joinNCT06956716 - No phaseTaking peoplePrognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma
- Where
- Chengdu
- Age
- 18 years and over
- People
- 50
- Run by
- West China Hospital
See details and how to joinNCT06950814 - No phaseTaking peopleTextbook Outcomes of Right Hemihepatectomy in Patients With Hepatocellular Carcinoma
- Where
- Chengdu
- Age
- 18 years and over
- People
- 400
- Run by
- West China Hospital
See details and how to joinNCT06950827 - Phase 2Taking peopleLenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 78
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT06904196 - Phase 2Not yet taking people in ChinaSecond-line Regimen Combined With Radiotherapy Versus Without Radiotherapy in Patients With Locally Advanced/Oligometastatic ICC After Failure of First-line Treatment:an Open-label, Randomized, Controlled Phase II Clinical Study
- Where
- Shanghai
- Age
- 18 years to 80 years
- People
- 76
- Run by
- Shanghai Zhongshan Hospital
See details and how to joinNCT06946849 - Early phase 1Taking peopleA Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients
- Where
- Shanghai
- Age
- 18 years and over
- People
- 37
- Run by
- Shanghai Changzheng Hospital
See details and how to joinNCT06418659 - Early phase 1Taking peopleA Clinical Trial Evaluating the Safety and Efficacy of Intravenous HNF4α srRNA in Treating Advanced ICC Patients
- Where
- Shanghai
- Age
- 18 years and over
- People
- 9
- Run by
- Shanghai Changzheng Hospital
See details and how to joinNCT06583993 - No phaseTaking peopleRaman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
- Where
- Hangzhou, Nanchang, Shanghai
- People
- 600
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06822413 - Phase 3Taking peopleToripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 480
- Run by
- Shanghai Junshi Bioscience Co., Ltd.
See details and how to joinNCT05342194 - No phaseTaking peopleReal-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors
- Where
- Shenyang
- Age
- 18 years and over
- People
- 120
- Run by
- Changchun GeneScience Pharmaceutical Co., Ltd.
See details and how to joinNCT06940102 - No phaseNot yet taking people in ChinaRelationship Between FGF19 Overexpression and Disease Prognosis
- Where
- Beijing
- Age
- 18 years and over
- People
- 100
- Run by
- Beijing Tsinghua Chang Gung Hospital
See details and how to joinNCT06938451 - Phase 2Not yet taking people in ChinaA Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 53
- Run by
- Shanghai Zhongshan Hospital
See details and how to joinNCT06935175 - Phase 4Taking peopleA Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk
- Where
- Zhengzhou
- Age
- 18 years to 75 years
- People
- 30
- Run by
- The First Affiliated Hospital of Zhengzhou University
See details and how to joinNCT06930573 - No phaseTaking peopleSIRT Versus cTACE for Unresectable HCC (CHANCE2506)
- Where
- Nanjing
- Age
- 18 years and over
- People
- 108
- Run by
- Zhongda Hospital
See details and how to joinNCT06909708